Core Viewpoint - The stock of Baiaosaitu-B (02315) has increased by over 5%, currently trading at 36.08 HKD, with a transaction volume of 27.5841 million HKD. The inclusion of Baiaosaitu in the Hong Kong Stock Connect list, effective from December 24, 2025, marks a significant milestone for the company in establishing its "A+H" dual capital market platform, opening its Hong Kong channel to mainland investors [1]. Group 1 - The stock price of Baiaosaitu-B has risen by 4.94% to 36.08 HKD, with a trading volume of 27.5841 million HKD [1]. - The Shanghai and Shenzhen Stock Exchanges announced the inclusion of Baiaosaitu in the Hong Kong Stock Connect list, effective December 24, 2025 [1]. - This inclusion is seen as a key milestone in the company's strategy to build a dual capital market platform [1]. Group 2 - Huafu Securities previously reported that the company's "thousand mice and ten thousand antibodies" strategy is beginning to yield results, with antibody licensing driving significant performance growth [1]. - The company is recognized for its high growth potential and strong barriers to entry, with a solid foundation in preclinical animal and pharmacological evaluations [1]. - The antibody development business is gradually entering a phase of performance realization, complemented by the potential of its new drug pipeline, leading to an initial "buy" rating [1].
百奥赛图-B再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现